Penbutolol patient counseling information: Difference between revisions

Latest revision as of 00:01, 22 July 2014

Redirect to:

@@ Line 1: / Line 1: @@
-__NOTOC__
+#REDIRECT [[Penbutolol#Patient Counseling Information]]
-{{Penbutolol}}
-{{CMG}}; {{AE}} {{SS}}
-==Patient Counseling Information==
-Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of levatol® without the physician’s advice. Although cardiac failure rarely occurs in properly selected patients, those being treated with ß-adrenergic receptor antagonists should be advised of the symptoms of heart failure and to report such symptoms immediately, should they develop.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LEVATOL (PENBUTOLOL SULFATE) TABLET [ACTIENT PHARMACEUTICALS, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d241fc80-2c55-4dbb-bdb2-44f731afa137 | publisher =  | date =  | accessdate = 4 February 2014 }}</ref>
-==References==
-{{Reflist|2}}
-[[Category:Beta blockers]]
-[[Category:Cardiovascular Drugs]]
-[[Category:Drugs]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}